| RYCIX | VCSAX | RYCIX / VCSAX | |
| Total Expense Ratio | 1.38 | 0.09 | 1,533% |
| Annual Report Gross Expense Ratio | 1.43 | 0.09 | 1,589% |
| Fund Existence | 28 years | 23 years | - |
| Gain YTD | 9.047 | 9.087 | 100% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 2500 | 100000 | 3% |
| Min. Initial Investment IRA | 1000 | N/A | - |
| Net Assets | 30.8M | 9.19B | 0% |
| Annual Yield % from dividends | 1.39 | 2.08 | 67% |
| Returns for 1 year | -10.41 | 6.61 | -158% |
| Returns for 3 years | -21.92 | 17.05 | -129% |
| Returns for 5 years | -32.86 | 24.91 | -132% |
| Returns for 10 years | -30.66 | 64.79 | -47% |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| SLGYX | 23.05 | 0.19 | +0.83% |
| Saratoga Large Capitalization Growth A | |||
| BERIX | 14.38 | -0.01 | -0.07% |
| Carillon Chartwell Real Income I | |||
| PCCGX | 12.40 | -0.03 | -0.24% |
| Victory Pioneer Mid Cap Value C | |||
| FCTGX | 35.88 | -0.28 | -0.77% |
| Fidelity Advisor Small Cap Growth M | |||
| FIJYX | 49.99 | -1.21 | -2.36% |
| Fidelity Advisor Biotechnology Z | |||